Skip to main content
medichelpline
Back to Clinical Feed
Try:
Front ImmunolInfectious Disease

Identification of a novel PANoptosis-associated prognostic signature and immune landscape analysis in neuroblastoma with experimental validation

26 May 20264 min read0 viewsJournal Feed

GIST

BackgroundNeuroblastoma (NB) is the most common extracranial pediatric solid tumor, and the prognosis of high-risk patients remains poor, while early diagnosis is still challenging. Although PANoptosis plays an important role in tumor development and progression, its role in NB has not been systematically investigated.MethodsGSE49710 (n = 498) was used as the training cohort, providing transcriptomic profiles and clinical annotations.

Patients were stratified by Children’s Oncology Group (COG) risk classification. PANoptosis core genes were defined as the intersection between differentially expressed genes (DEGs) associated with COG risk and a curated PANoptosis gene set.

Based on those core genes, consensus clustering analysis stratified patients into PANoptosis-related clusters (PANclusters). Differential gene analysis, survival analysis, and gene set variation analysis (GSVA) in PANclusters were conducted subsequently.

Weighted gene co-expression network analysis (WGCNA) was applied to identify co-expression modules most strongly associated with PANclusters. Candidate genes were further subjected to Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analyses to construct a prognostic model (NB index).

Clinical Editorial

Summary

Frontiers in Immunology published a clinical update in Infectious Disease on 26 May 2026.

The item focuses on Identification of a novel PANoptosis-associated prognostic signature and immune landscape analysis in neuroblastoma with experimental validation.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.